Vanda Pharmaceuticals Inc. (VNDA)
Largest Insider Buys in Sector
VNDA Stock Price History Chart
VNDA Stock Performance
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Activity of Vanda Pharmaceuticals Inc.
Over the last 12 months, insiders at Vanda Pharmaceuticals Inc. have bought $0 and sold $588,385 worth of Vanda Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Vanda Pharmaceuticals Inc. have bought $0 and sold $3.55M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 11,170 shares for transaction amount of $100,156 was made by Flynn James E (10 percent owner) on 2015‑12‑16.
List of Insider Buy and Sell Transactions, Vanda Pharmaceuticals Inc.
| 2024-03-05 | Sale | Polymeropoulos Mihael Hristos | President and CEO | 24,288 0.0421% | $4.13 | $100,273 | +18.89% | |
| 2024-03-05 | Sale | Birznieks Gunther | SVP, Business Development | 8,684 0.0151% | $4.13 | $35,884 | +18.89% | |
| 2024-03-05 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 8,902 0.0157% | $4.20 | $37,411 | +18.89% | |
| 2024-03-05 | Sale | Williams Timothy | SVP & General Counsel | 8,941 0.0157% | $4.18 | $37,396 | +18.89% | |
| 2024-03-05 | Sale | Wijkstrom Joakim | SVP, Chief Marketing Officer | 9,229 0.0163% | $4.21 | $38,830 | +18.89% | |
| 2024-03-04 | Sale | Polymeropoulos Mihael Hristos | President and CEO | 30,884 0.0534% | $4.24 | $131,066 | +14.37% | |
| 2024-03-04 | Sale | Birznieks Gunther | SVP, Business Development | 8,727 0.0153% | $4.30 | $37,495 | +14.37% | |
| 2024-03-04 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 5,798 0.0106% | $4.48 | $25,982 | +14.37% | |
| 2024-03-04 | Sale | Williams Timothy | SVP & General Counsel | 8,147 0.0146% | $4.41 | $35,917 | +14.37% | |
| 2024-03-04 | Sale | Wijkstrom Joakim | SVP, Chief Marketing Officer | 7,498 0.0135% | $4.41 | $33,091 | +14.37% | |
| 2023-08-21 | Sale | Wijkstrom Joakim | SVP, Chief Marketing Officer | 3,724 0.0064% | $5.84 | $21,748 | -26.94% | |
| 2023-08-10 | Sale | Mitchell Stephen Ray | director | 6,500 0.0114% | $6.05 | $39,349 | -27.57% | |
| 2023-07-28 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 2,212 0.0038% | $6.30 | $13,945 | -26.26% | |
| 2023-06-15 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 16,000 0.0279% | $6.29 | $100,710 | -29.57% | |
| 2023-06-13 | Sale | Williams Timothy | SVP & General Counsel | 14,600 0.0257% | $6.56 | $95,754 | -31.65% | |
| 2023-03-03 | Sale | Polymeropoulos Mihael Hristos | President and CEO | 22,538 0.0388% | $6.25 | $140,876 | -19.78% | |
| 2023-03-03 | Sale | Birznieks Gunther | SVP, Business Development | 8,268 0.0143% | $6.26 | $51,791 | -19.78% | |
| 2023-03-03 | Sale | Moran Kevin Patrick | SVP, CFO & Treasurer | 5,968 0.0103% | $6.28 | $37,499 | -19.78% | |
| 2023-03-03 | Sale | Wijkstrom Joakim | SVP, Chief Marketing Officer | 4,113 0.0072% | $6.32 | $25,994 | -19.78% | |
| 2023-03-03 | Sale | Williams Timothy | SVP & General Counsel | 8,301 0.0143% | $6.25 | $51,887 | -19.78% |
Insider Historical Profitability
| Polymeropoulos Mihael Hristos | President and CEO | 1871730 2.5671% | $5.98 | 5 | 52 | <0.0001% |
| Birznieks Gunther | SVP, Business Development | 313569 0.358% | $5.98 | 0 | 17 | |
| Moran Kevin Patrick | SVP, CFO & Treasurer | 231014 0.2098% | $5.98 | 0 | 13 | |
| Wijkstrom Joakim | SVP, Chief Marketing Officer | 129789 0.1978% | $5.98 | 0 | 10 | |
| Williams Timothy | SVP & General Counsel | 196825 0.1545% | $5.98 | 0 | 16 | |
| Mitchell Stephen Ray | director | 29328 0.051% | $5.98 | 0 | 4 | |
| TANG KEVIN C | 10 percent owner | 2715852 4.7206% | $5.98 | 6 | 8 | +419.54% |
| RHO VENTURES IV LP | 10 percent owner | 1862692 3.2377% | $5.98 | 0 | 2 | |
| Biomedical Sciences Investment Fund Pte Ltd. | 10 percent owner | 1856957 3.2277% | $5.98 | 0 | 5 | |
| Flynn James E | 10 percent owner | 693171 1.2048% | $5.98 | 5 | 5 | +15.47% |
| Kelly James Patrick | EVP & Chief Financial Officer | 186869 0.3248% | $5.98 | 1 | 14 | <0.0001% |
| Clark William D | Sr. VP, Chief Business Officer | 168279 0.2925% | $5.98 | 1 | 10 | <0.0001% |
| Reverberi Gian Piero | SVP & Chief Commercial Officer | 165384 0.2875% | $5.98 | 0 | 5 | |
| CARE CAPITAL II LLC | 10 percent owner | 121546 0.2113% | $5.98 | 0 | 7 | |
| Gulino Richard L. | SVP, General Counsel & Sec. | 115073 0.2% | $5.98 | 0 | 3 | |
| Jones Aranthan II | Chief Corp. Affairs Officer | 81980 0.1425% | $5.98 | 0 | 7 | |
| DUGAN RICHARD W | 68387 0.1189% | $5.98 | 0 | 5 | ||
| Watkins Thomas | 63064 0.1096% | $5.98 | 0 | 4 | ||
| Baroldi Paolo | SVP & Chief Medical Officer | 54365 0.0945% | $5.98 | 0 | 3 | |
| TREU JESSE I | 10 percent owner | 21068 0.0366% | $5.98 | 0 | 1 | |
| BLAIR JAMES C | director | 21068 0.0366% | $5.98 | 0 | 1 | |
| DOVEY BRIAN H | 10 percent owner | 21068 0.0366% | $5.98 | 0 | 1 | |
| MORE ROBERT J | 10 percent owner | 21068 0.0366% | $5.98 | 0 | 1 | |
| VITULLO NICOLE | 10 percent owner | 21068 0.0366% | $5.98 | 0 | 1 | |
| SCHOEMAKER KATHLEEN K | 10 percent owner | 21068 0.0366% | $5.98 | 0 | 1 | |
| DP VI Associates, L.P. | 10 percent owner | 21068 0.0366% | $5.98 | 0 | 1 | |
| Repella Robert | SVP & Chief Commercial Officer | 15000 0.0261% | $5.98 | 0 | 3 | |
| Chrousos Phaedra | director | 12925 0.0225% | $5.98 | 0 | 1 | |
| Feeney John Joseph | SVP & Chief Medical Officer | 11942 0.0208% | $5.98 | 0 | 8 | |
| TANANBAUM JAMES B | director | 11041 0.0192% | $5.98 | 0 | 2 | |
| Irish Stephanie Rast | Acting CFO/Treasurer | 2249 0.0039% | $5.98 | 0 | 3 | |
| Ramsay David Russ | 0 0% | $5.98 | 0 | 19 | ||
| KARABELAS ARGERIS N | director | 0 0% | $5.98 | 0 | 19 | |
| SHALLCROSS STEVEN A | Sr. VP, CFO, Treasurer | 0 0% | $5.98 | 0 | 13 | |
| Phadke Deepak Shripad | Vice President Manufacturing | 0 0% | $5.98 | 0 | 1 |
Institutional Investor Ownership
| BlackRock | $33.45M | 13.99 | 8.14M | -2.47% | -$848,657.44 | <0.01 | |
| Renaissance Technologies | $17.57M | 7.35 | 4.28M | +16.15% | +$2.44M | 0.03 | |
| The Vanguard Group | $13.96M | 5.84 | 3.4M | -1.75% | -$248,671.42 | <0.0001 | |
| Acadian Asset Management | $9.74M | 4.07 | 2.37M | +4.74% | +$440,510.40 | 0.03 | |
| D. E. Shaw & Co. | $7.41M | 3.1 | 1.8M | -14.64% | -$1.27M | 0.01 | |
| Tang Capital Management, LLC | $7.2M | 3.01 | 1.75M | +605.77% | +$6.18M | 0.03 | |
| Dimensional Fund Advisors | $7.08M | 2.96 | 1.72M | -12.52% | -$1.01M | <0.01 | |
| Morgan Stanley | $6.2M | 2.59 | 1.51M | -25.42% | -$2.11M | <0.0001 | |
| Jacobs Levy Equity Management | $5.83M | 2.44 | 1.42M | -0.72% | -$42,291.90 | 0.03 | |
| Geode Capital Management | $5.12M | 2.14 | 1.25M | <0.01% | -$497.37 | <0.0001 | |
| Bank of America | $4.97M | 2.08 | 1.21M | +4,351.14% | +$4.85M | <0.0001 | |
| State Street | $4.95M | 2.07 | 1.2M | -2.02% | -$101,932.10 | <0.0001 | |
| Prudential Financial | $4.51M | 1.89 | 1.1M | -28.57% | -$1.81M | 0.01 | |
| Nantahala Capital Management Llc | $4.16M | 1.74 | 1.01M | 0% | +$0 | 0.43 | |
| Assenagon Asset Management S.A. | $3M | 1.26 | 730,820 | -53.97% | -$3.52M | 0.01 | |
| Citadel Advisors LLC | $2.98M | 1.25 | 725,239 | +17.16% | +$436,617.59 | <0.01 | |
| Federated Hermes | $2.94M | 1.23 | 715,670 | -12.51% | -$420,687.31 | 0.01 | |
| Two Sigma Advisers LP | $2.89M | 1.21 | 703,900 | -20.6% | -$750,486.00 | 0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $2.85M | 1.19 | 692,878 | +161.02% | +$1.76M | 0.01 | |
| Charles Schwab | $2.75M | 1.15 | 668,180 | +3.57% | +$94,739.62 | <0.01 | |
| Two Sigma | $2.19M | 0.92 | 532,280 | -32.02% | -$1.03M | <0.01 | |
| Bridgeway Capital Management | $2.16M | 0.9 | 526,383 | +45.74% | +$679,033.61 | 0.04 | |
| SEI Investments Company | $2.13M | 0.89 | 518,851 | +39.56% | +$604,441.37 | <0.01 | |
| Goldman Sachs | $2.08M | 0.87 | 505,385 | +9.58% | +$181,546.89 | <0.0001 | |
| Northern Trust | $2.03M | 0.85 | 494,740 | -2.72% | -$56,902.97 | <0.0001 | |
| Gsa Capital Partners Llp | $2.01M | 0.84 | 489,324 | -13.81% | -$322,336.02 | 0.16 | |
| Wellington Management Company | $1.79M | 0.75 | 435,767 | New | +$1.79M | <0.0001 | |
| Millennium Management LLC | $1.78M | 0.74 | 432,802 | -56.65% | -$2.32M | <0.01 | |
| Los Angeles Capital Management LLC | $1.77M | 0.74 | 431,224 | +17.64% | +$265,793.75 | 0.01 | |
| APG Asset Management | $1.42M | 0.64 | 371,900 | -12.64% | -$204,738.87 | <0.01 | |
| Qube Research & Technologies | $1.52M | 0.64 | 370,246 | -9.52% | -$160,154.36 | <0.01 | |
| Invesco | $1.36M | 0.57 | 330,639 | +144.94% | +$804,125.44 | <0.0001 | |
| Newtyn Management | $1.28M | 0.53 | 311,000 | +7.24% | +$86,310.00 | 0.28 | |
| Nuveen | $1.24M | 0.52 | 302,650 | +95.57% | +$607,868.76 | <0.0001 | |
| Susquehanna Fundamental Investments Llc | $1.16M | 0.48 | 281,683 | New | +$1.16M | 0.05 | |
| JPMorgan Chase | $1.15M | 0.48 | 280,783 | +36.28% | +$307,230.95 | <0.0001 | |
| American Century Investments | $1.03M | 0.43 | 251,238 | +8.06% | +$77,033.72 | <0.01 | |
| Ameriprise Financial | $1M | 0.42 | 244,241 | -18.38% | -$225,976.13 | <0.0001 | |
| BNY Mellon | $975,196.00 | 0.41 | 237,274 | -6.95% | -$72,870.29 | <0.0001 | |
| Squarepoint Ops LLC | $968,328.00 | 0.41 | 235,603 | -42.22% | -$707,577.36 | <0.01 | |
| Profit Investment Management | $905,531.00 | 0.38 | 220,324 | -43.4% | -$694,384.01 | 0.52 | |
| Victory Capital Management Inc | $890,707.00 | 0.37 | 216,717 | +72.92% | +$375,617.07 | <0.01 | |
| Empowered Funds Llc | $827,273.00 | 0.35 | 201,283 | +8.18% | +$62,533.64 | 0.02 | |
| Winton Capital Management | $673,325.00 | 0.28 | 163,826 | +44.86% | +$208,516.78 | 0.04 | |
| Allspring Global Investments | $659,536.00 | 0.28 | 160,471 | -36.1% | -$372,637.37 | <0.01 | |
| Susquehanna International Group | $642,853.00 | 0.27 | 156,412 | -35.5% | -$353,842.05 | <0.01 | |
| Tudor Investment Corp Et Al | $571,454.00 | 0.24 | 139,040 | +281.85% | +$421,800.78 | 0.01 | |
| Massachusetts Financial Services Co Ma | $560,357.00 | 0.23 | 136,340 | -0.22% | -$1,245.33 | <0.0001 | |
| Barclays | $516,000.00 | 0.22 | 125,676 | -26.78% | -$188,710.59 | <0.0001 | |
| Public Employees Retirement System Of Ohio | $480,467.00 | 0.2 | 116,902 | -4.14% | -$20,739.05 | <0.01 |